Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago

Possible Interaction: Levocarnitine and Doxorubicin Hydrochloride

Research Papers that Mention the Interaction

This mechanism can be proposed to explain the protective effects of L-carnitine against adriamycin cardiotoxicity, ammonium acetate and zidovudine-induced mitochondrial ultrastructural and functional alterations.
Drugs under experimental and clinical research  •  2001  |  View Paper
TO THE EDITOR: Missing from Shan and colleagues' interesting review of anthracycline-induced cardiotoxicity [1] is any reference to the potential use of L-carnitine to prevent adriamycin cardiotoxicity.
Annals of Internal Medicine  •  1997  |  View Paper
In conclusion, data from this study suggest that the reduction of antioxidant defense during doxorubicin administration resulted in hepatic injury could be prevented by L-carnitine supplementation by decreasing the oxidative stress and preserving both the activity and gene expression level of antioxidant enzymes.
Interestingly, L-carnitine supplementation completely reversed the biochemical and gene expression levels induced by doxorubicin to the control values.
The present study investigates whether L-carnitine , antioxidant agent, can reduce the hepatic damage induced by doxorubicin.
Oxidative medicine and cellular longevity  •  2010  |  View Paper
Biopharmacological evaluations suggest that L-carnitine can prevent cardiac metabolic damage caused by doxorubicin , as well as can inhibit cisplatin-induced injury in the kidney and in the small intestine, without any interference with the drug's antitumoral properties.
Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie  •  2009  |  View Paper
ADR treatment resulted in elevation of plasma free and total CARN concentrations (p < 0.05).
Pediatric Research  •  2003  |  View Paper
Perfusion of the heart with L-carnitine after 10-min perfusion with DOX (0.5 mM) caused 88% reversal of DOX-induced inhibition of palmitate oxidation in cardiac cells.
Pharmacological research  •  1999  |  View Paper
However, the oxidation of a non-CPT 1 dependent substrate palmitoylcarnitine was unaffected by adriamycin except … than 1 mM. These data suggest that after in vitro or in vivo administration, adriamycin , inhibits fatty acid oxidation in part secondary to … 1 and/or depletion of its substrate, L-carnitine , in ….
Interestingly, medium- and short-chain fatty acid oxidation, which are independent of CPT 1, were also inhibited acutely by adriamycin and could be reversed by L-carnitine.
Journal of molecular and cellular cardiology  •  1997  |  View Paper
Incubation for 60 min with a mixture of L-carnitine and doxorubicin improved cellular respiration, oxygen uptake being only 9% less than that of the controls, and an even greater reversal characterized the propionyl carnitine mixture for which the recovery of endogenous cellular respiration was almost complete (93%).
Oncology  •  1988  |  View Paper
L-carnitine moreover acts to eliminate completely the Ca2+ increase induced by doxorubicin.
L-carnitine pre-incubation significantly reduced (p less than 0.001) the metabolic cardiac impairment due to doxorubicin.
Thus, it appears L-carnitine may be useful in the prevention of doxorubicin-induced cardiac toxicity.
Anticancer research  •  1986  |  View Paper
This would suggest that the reparatory effect of L-Carnitine against Doxorubicin cardiotoxicity is linked to the natural role played by this substance in metabolic processes.
Biomedicine / [publiee pour l'A.A.I.C.I.G.]  •  1981  |  View Paper
Show More